Pharma news
Pharma
The Court of Justice of the European Union has clarified when pharmaceutical patent owners may rely on the Specific Mechanism to prevent parallel imports of their products. 19 February 2015
Pharma
The tussle between Teva and Amgen over the latter’s SPC for lipegfilgrastim is still playing out in Denmark’s IP court and may yet be referred to the CJEU. Michael Pitzner-Bruun of law firm Kromann Reumert reports. 19 February 2015
Pharma
The unitary patent and Unified Patent Court will have wide-ranging implications for life sciences companies. In the first of what will be a regular column on the topics by law firm Taylor Wessing, Paul England explores current developments on issues such as costs and judges. 19 February 2015
Pharma
A US court has ruled that an AstraZeneca patent covering asthma inhaler Pulmicort Respules is invalid, allowing generic drug makers to enter the market with their own versions. 17 February 2015
Americas
Novartis has sued drug company BPI Labs for alleged patent infringement after it requested permission to market a generic version of Novartis’s bone cancer drug Zometa. 12 February 2015
Pharma
A medical aid non-profit organisation has opposed a European patent held by pharmaceutical company Gilead that covers its anti-hepatitis C drug Sovaldi. 11 February 2015
Asia
Another party has thrown its hat into the ring in the fight to stop the issue of an Indian patent covering Sovaldi, a hepatitis C drug. 4 February 2015
Americas
The most recent Illicit Trade Report states that pharmaceuticals are by far the most numerous counterfeit commodity reported, and the problem is increasing. LSIPR investigates what’s being done about it. 30 January 2015
Americas
Despite the headwinds facing the industry, a growing number of leading pharmaceutical companies feature on Thomson Reuters’ annual Top 100 Global Innovators list, as Bob Stembridge reports. 30 January 2015
Americas
Existing portfolios should be carefully reviewed and care must be taken in drafting new patent applications to withstand section 101 scrutiny in the US, as Judith Kim, director, and Scott Schaller, of counsel, at Sterne Kessler Goldstein & Fox, describe. 30 January 2015